Efficacy News and Research

RSS

RPCI researchers create outreach effort to improve public's participation in biomedical research

Roswell Park Cancer Institute researchers, together with input from African-American community leaders in Buffalo, have created an outreach effort that provides racial/ethnic minority and medically underserved communities with educational programs regarding the public's participation in biomedical research. The program is the basis of a recent study published by a team of local collaborators.

18 Aug 2015

EPGL challenges Google in smart contact lens revolution

EP Global Communications, Inc. announces a challenge to Google to confirm it is up to speed with EPGL in the smart contact lens revolution.

18 Aug 2015

Reducing amyloid fibril levels in semen may help reduce transmission of HIV

There may be two new ways to fight AIDS -- using a heat shock protein or a small molecule - to attack fibrils in semen associated with the human immunodeficiency virus (HIV) during the initial phases of infection, according to new research from the Perelman School of Medicine at the University of Pennsylvania.

18 Aug 2015

Molecular tweezer blocks HIV, breaks up proteins in semen that boost infection

An unprecedented potential "molecular tweezer" called CLR01, reported in the journal eLife, not only blocks HIV and other sexually transmitted viruses, but also breaks up proteins in semen that boost infection.

18 Aug 2015

Kuros Biosurgery closes financing round of CHF15M

Kuros Biosurgery AG, a biotechnology company developing novel biomaterials and bioactive-biomaterial combination products and focused in therapeutic areas covering sealants and orthobiologics, announced today that it has closed a financing round of CHF15M. An additional investment is expected in a second closing later this year.

18 Aug 2015

New OTEMTO phase three results show potential improvement to quality of life for COPD patients

Boehringer Ingelheim announced the publication of new data from the Phase IIIb OTEMTO® 1&2 trials (NCT01964352/NCT02006732), which show Spiolto® Respimat® (tiotropium/olodaterol) provides consistent, clinically meaningful improvements in quality of life versus placebo in patients with COPD

17 Aug 2015

DelMar obtains additional funding to support ongoing research project with lead product candidate VAL-083

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced an increase in funding of up to CDN$287,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) to support an ongoing research project.

17 Aug 2015

NanoViricides speeds up HerpeCide drug development program

NanoViricides, Inc., a nanomedicine company developing anti-viral drugs, reports that it is accelerating its HerpeCide drug development program.

17 Aug 2015

FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

Chiasma, Inc., a U.S. late-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application (NDA) for the marketing and sale of octreotide capsules, an oral drug proposed for the maintenance therapy of adult patients with acromegaly.

17 Aug 2015

Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

United Therapeutics Corporation announced today that the European Commission (EC) has granted Marketing Authorisation for Unituxin (dinutuximab) for the treatment of high-risk neuroblastoma in patients aged 12 months to 17 years, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and autologous stem cell transplantation (ASCT).

17 Aug 2015

Risk for endophthalmitis no higher with Avastin, finds study

Eye injections of the drug Avastin, used to treat retinal diseases, bring no greater risk of endophthalmitis, a potentially blinding eye infection, than injections with the much more expensive drug Lucentis made by the same company, according to new research from the Perelman School of Medicine at the University of Pennsylvania. Their findings are published today in JAMA Ophthalmology.

14 Aug 2015

Neurocrine completes enrollment in Phase III clinical trial of NBI-98854 in tardive dyskinesia patients

Neurocrine Biosciences, Inc. announced today that it has recently completed subject randomization of the Phase III clinical trial (Kinect 3 Study) of its proprietary Vesicular Mono-Amine Transporter 2 (VMAT2) compound NBI-98854 in tardive dyskinesia patients.

13 Aug 2015

Rhythm Metabolic completes $40 million Series A financing

Rhythm announced today the completion of a $40 million Series A financing for its subsidiary, Rhythm Metabolic, Inc., which is developing setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway.

13 Aug 2015

ImmunoCellular signs agreement with FDA for phase 3 registrational trial of cancer immunotherapy ICT-107

ImmunoCellular Therapeutics, Ltd. announced today that it has reached agreement with the US Food and Drug Administration on a Special Protocol Assessment (SPA) for the phase 3 registrational trial of its cancer immunotherapy ICT-107 to treat patients with newly diagnosed glioblastoma.

13 Aug 2015

ESC Congress to highlight results from global trials in six press conferences

Members of the press will be the first to hear the highly anticipated results from global trials in six press conferences devoted to hot lines research.

13 Aug 2015

RSAM, Rettsyndrome.org renew commitment to jointly defeat Rett syndrome

The Rett Syndrome Association of Massachusetts and Rettsyndrome.org announce today their renewed commitment to work together to defeat Rett syndrome. A generous $85,000 donation from RSAM will support an ongoing clinical trial for Rettsyndrome.org at Boston Children's Hospital.

13 Aug 2015

First clinical trial to test use of retinal progenitor cells for treating retinitis pigmentosa begins

Participants are being enrolled in the first clinical trial that tests the use of retinal progenitor cells to treat retinitis pigmentosa, reported project director Dr. Henry Klassen of UCI's Gavin Herbert Eye Institute and Sue & Bill Gross Stem Cell Research Center. The product of stem cell research at UCI, these retinal progenitors are similar to stem cells in terms of potential regenerative properties, but they're specific to the retina.

13 Aug 2015

Researchers analyze inclusion/exclusion criteria used in antidepressant efficacy studies

Mark Zimmerman, M.D., a clinical researcher at Rhode Island Hospital, and his team analyzed the criteria used in antidepressant efficacy studies (AETs) and learned that the inclusion/exclusion criteria for AETs have narrowed over the past five years so that the most patients are excluded. The research was published today in Mayo Clinic Proceedings.

13 Aug 2015

$AbbVie's venetoclax Phase 2 trial meets primary endpoint in patients with relapsed/refractory CLL with 17P deletion$

AbbVie's venetoclax Phase 2 trial meets primary endpoint in patients with relapsed/refractory CLL with 17P deletion

AbbVie, a global biopharmaceutical company, today announced that a Phase 2 trial of its investigational medicine venetoclax met its primary endpoint of achieving overall response rates in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia (CLL) with 17p deletion, according to an independent review analysis.

12 Aug 2015

Ardelyx reports net income of $9.0 million for second quarter 2015

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced financial results for the second quarter ended June 30, 2015.

12 Aug 2015

Efficacy News and Research

RPCI researchers create outreach effort to improve public's participation in biomedical research

EPGL challenges Google in smart contact lens revolution

Reducing amyloid fibril levels in semen may help reduce transmission of HIV

Molecular tweezer blocks HIV, breaks up proteins in semen that boost infection

Kuros Biosurgery closes financing round of CHF15M

New OTEMTO phase three results show potential improvement to quality of life for COPD patients

DelMar obtains additional funding to support ongoing research project with lead product candidate VAL-083

NanoViricides speeds up HerpeCide drug development program

FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

Risk for endophthalmitis no higher with Avastin, finds study

Neurocrine completes enrollment in Phase III clinical trial of NBI-98854 in tardive dyskinesia patients

Rhythm Metabolic completes $40 million Series A financing

ImmunoCellular signs agreement with FDA for phase 3 registrational trial of cancer immunotherapy ICT-107

ESC Congress to highlight results from global trials in six press conferences

RSAM, Rettsyndrome.org renew commitment to jointly defeat Rett syndrome

First clinical trial to test use of retinal progenitor cells for treating retinitis pigmentosa begins

Researchers analyze inclusion/exclusion criteria used in antidepressant efficacy studies

AbbVie's venetoclax Phase 2 trial meets primary endpoint in patients with relapsed/refractory CLL with 17P deletion

Ardelyx reports net income of $9.0 million for second quarter 2015

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News